Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease.

Proceedings of the Western Pharmacology Society - 1 Jan 2008

Helsby Nuala A

Abstract excerpt

A genotyping approach for pharmacogenes such as CYP2C19 is often advocated to "personalise therapy", since individuals with the homozygous null allele genotype are poor metabolisers (PM) of many drugs. The genotype-phenotype relationship is a validated approach for S-mephenytoin, proguanil and omeprazole in young, healthy populations. However, this relationship may not be valid in patients with diseases such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19
Share to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ethnicity

Share to Gene Expression Regulation

Share to Genetic Variation

Share to Inactivation, Metabolic

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 19544664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease.PMID 19544664Read ↗

CYP2C19 genotype-phenotype correlation: current insights and unanswered questionsSemantic proximity Read ↗

Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction.Semantic proximity Read ↗

Cytochrome P450: genotype to phenotypeSemantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Semantic proximity Read ↗

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.Semantic proximity Read ↗

CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.Semantic proximity Read ↗

CYP2C19 and CYP2D6 genotypes in Pacific peoples.Semantic proximity Read ↗

Addressing phenoconversion: the Achilles' heel of personalized medicine.Semantic proximity Read ↗

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.Semantic proximity Read ↗

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.Semantic proximity Read ↗

The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.